Under real-world conditions, there is no excess risk for ONJ in osteoporosis patients >50 years old using alendronate as compared with patients using raloxifene or calcitonin.

A pharmacoepidemiology study was conducted using the health insurance database in Taiwan to assess compliance with osteoporosis drug regimens and the impact of compliance on the risk for secondary fractures. Patients >50 years of age with vertebral/hip fracture who had been started on alendronate therapy for the first time only after the fracture were included. Compliance was measured using the medication possession ratio (MPR) and was included as a time-dependent covariate in the Cox model to compare the difference between compliant (MPR ≥ 80%) and noncompliant patients (MPR <80%) with respect to risk for subsequent hip fractures. Only 38% of the study population remained compliant during the first year of treatment. Over the 4-year follow-up period, the risk of hip fracture among the compliant patients was 70% lower than that among the noncompliant ones (adjusted hazard ratio (HR) 0.30). Among patients with osteoporosis in Taiwan who had experienced a fracture and had started alendronate therapy, compliance with the dosage regimen was suboptimal. It was also found that compliance significantly reduced the risk of secondary hip fracture up to 4 years.

No abstract

An enhanced process for microencapsulating aspirin in ethylcellulose was demonstrated using an oil-in-water emulsification/solvent evaporation technique. Methylene chloride (CH2Cl2) was used as the dispersed medium and water as the dispersing medium. The recovered weight, particle size distribution, aspirin loading efficiency, and the aspirin release rate of microcapsules were analysed. The addition of appropriate amounts of non-solvent (n-heptane) prior to the emulsification increases the recovered weight, but decreases the size of the formed microcapsules. The addition of non-solvent also changes the microcapsule characteristics, resulting in a coarser surface and an increased release rate. Increasing the polymer (ethylcellulose) concentration in the dispersed phase increases the size of the microcapsules, the recovered weight, and loading efficiency, but decreases the release rate. The release rate follows first-order kinetics during the first 12 h, suggesting a monolithic system with aspirin uniformly distributed in the microcapsule.

No abstract

No abstract

No abstract